Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer.

Kuninty PR, Bansal R, De Geus SWL, Mardhian DF, Schnittert J, van Baarlen J, Storm G, Bijlsma MF, van Laarhoven HW, Metselaar JM, Kuppen PJK, Vahrmeijer AL, Östman A, Sier CFM, Prakash J.

Sci Adv. 2019 Sep 4;5(9):eaax2770. doi: 10.1126/sciadv.aax2770. eCollection 2019 Sep.

PMID:
31517053
2.

International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.

van Roessel S, Kasumova GG, Verheij J, Najarian RM, Maggino L, de Pastena M, Malleo G, Marchegiani G, Salvia R, Ng SC, de Geus SW, Lof S, Giovinazzo F, van Dam JL, Kent TS, Busch OR, van Eijck CH, Koerkamp BG, Abu Hilal M, Bassi C, Tseng JF, Besselink MG.

JAMA Surg. 2018 Dec 1;153(12):e183617. doi: 10.1001/jamasurg.2018.3617. Epub 2018 Dec 19. Erratum in: JAMA Surg. 2019 Feb 20;:.

PMID:
30285076
3.

Unique predictors and economic burden of superficial and deep/organ space surgical site infections following pancreatectomy.

Fadayomi AB, Kasumova GG, Tabatabaie O, de Geus SWL, Kent TS, Ng SC, Moser AJ, Callery MP, Ashley SW, Tseng JF.

HPB (Oxford). 2018 Jul;20(7):658-668. doi: 10.1016/j.hpb.2018.01.008. Epub 2018 Mar 9.

4.

Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma.

de Geus SWL, Kasumova GG, Sachs TE, Ng SC, Kent TS, Moser AJ, Vahrmeijer AL, Callery MP, Tseng JF.

HPB (Oxford). 2018 Jun;20(6):573-581. doi: 10.1016/j.hpb.2017.12.004. Epub 2018 Feb 6.

5.

Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study.

de Geus SWL, Kasumova GG, Eskander MF, Ng SC, Kent TS, James Moser A, Vahrmeijer AL, Callery MP, Tseng JF.

J Gastrointest Surg. 2018 Feb;22(2):214-225. doi: 10.1007/s11605-017-3541-8. Epub 2017 Oct 4.

PMID:
29235000
6.

Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.

de Geus SWL, Eskander MF, Kasumova GG, Ng SC, Kent TS, Mancias JD, Callery MP, Mahadevan A, Tseng JF.

Cancer. 2017 Nov 1;123(21):4158-4167. doi: 10.1002/cncr.30856. Epub 2017 Jul 14. Review.

7.

Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.

de Geus SW, Baart VM, Boonstra MC, Kuppen PJ, Prevoo HA, Mazar AP, Bonsing BA, Morreau H, van de Velde CJ, Vahrmeijer AL, Sier CF.

Biomark Insights. 2017 Jun 22;12:1177271917715443. doi: 10.1177/1177271917715443. eCollection 2017. Review.

8.

Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy.

Kasumova GG, Eskander MF, de Geus SWL, Neto MM, Tabatabaie O, Ng SC, Miksad RA, Mahadevan A, Rodrigue JR, Tseng JF.

Surgery. 2017 Aug;162(2):275-284. doi: 10.1016/j.surg.2017.03.009. Epub 2017 May 6.

PMID:
28487044
9.

Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.

de Geus SW, Eskander MF, Bliss LA, Kasumova GG, Ng SC, Callery MP, Tseng JF.

Surgery. 2017 Mar;161(3):592-601. doi: 10.1016/j.surg.2016.08.040. Epub 2016 Oct 27.

PMID:
28341441
10.

Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer.

Eskander MF, de Geus SW, Kasumova GG, Ng SC, Al-Refaie W, Ayata G, Tseng JF.

Surgery. 2017 Apr;161(4):968-976. doi: 10.1016/j.surg.2016.09.032. Epub 2016 Nov 17.

PMID:
27865602
11.

Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.

de Geus SW, Boogerd LS, Swijnenburg RJ, Mieog JS, Tummers WS, Prevoo HA, Sier CF, Morreau H, Bonsing BA, van de Velde CJ, Vahrmeijer AL, Kuppen PJ.

Mol Imaging Biol. 2016 Dec;18(6):807-819.

12.

Massachusetts Healthcare Reform and Trends in Emergent Colon Resection.

Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF.

Dis Colon Rectum. 2016 Nov;59(11):1063-1072.

PMID:
27749482
13.

Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.

Boonstra MC, de Geus SW, Prevoo HA, Hawinkels LJ, van de Velde CJ, Kuppen PJ, Vahrmeijer AL, Sier CF.

Biomark Cancer. 2016 Sep 27;8:119-133. eCollection 2016. Review.

14.

Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis.

de Geus SW, Evans DB, Bliss LA, Eskander MF, Smith JK, Wolff RA, Miksad RA, Weinstein MC, Tseng JF.

Eur J Surg Oncol. 2016 Oct;42(10):1552-60. doi: 10.1016/j.ejso.2016.07.016. Epub 2016 Aug 9.

PMID:
27570116
15.

Early surgical bypass versus endoscopic stent placement in pancreatic cancer.

Bliss LA, Eskander MF, Kent TS, Watkins AA, de Geus SW, Storino A, Ng SC, Callery MP, Moser AJ, Tseng JF.

HPB (Oxford). 2016 Aug;18(8):671-7. doi: 10.1016/j.hpb.2016.05.008. Epub 2016 Jun 11.

16.

A Tale of Two Cities: Reconsidering Adjuvant Radiation in Pancreatic Cancer Care.

de Geus SW, Bliss LA, Eskander MF, Ng SC, Vahrmeijer AL, Mahadevan A, Kent TS, Moser AJ, Callery MP, Bonsing BA, Tseng JF.

J Gastrointest Surg. 2016 Jan;20(1):85-92; discussion 92. doi: 10.1007/s11605-015-2951-8. Epub 2015 Oct 1.

PMID:
26427374
17.

Surgical management of chronic pancreatitis: current utilization in the United States.

Bliss LA, Yang CJ, Eskander MF, de Geus SW, Callery MP, Kent TS, Moser AJ, Freedman SD, Tseng JF.

HPB (Oxford). 2015 Sep;17(9):804-10. doi: 10.1111/hpb.12459. Epub 2015 Jul 27.

18.

A nationwide assessment of outcomes after bile duct reconstruction.

Eskander MF, Bliss LA, Yousafzai OK, de Geus SW, Ng SC, Callery MP, Kent TS, Moser AJ, Khwaja K, Tseng JF.

HPB (Oxford). 2015 Sep;17(9):753-62. doi: 10.1111/hpb.12436. Epub 2015 Jun 20.

Supplemental Content

Loading ...
Support Center